文献速递细菌感染、耐药与抗菌药物

澳大利亚2015-2018年艰难梭菌抗菌药物耐药性监测

Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

CDARS研究对澳大利亚5州10个实验室3年间收集的1091株艰难梭菌用CLSI琼脂掺入法检测9种抗菌药物敏感性。所有菌株对甲硝唑、非达霉素、利福昔明和阿莫西林/克拉维酸敏感,克林霉素耐药率高达85.2%,万古霉素耐药率5.7%,MDR占1.7%。

要点

  • 澳大利亚艰难梭菌对甲硝唑、非达霉素、利福昔明和阿莫西林/克拉维酸均敏感。
  • 克林霉素耐药率85.2%,头孢曲松耐药率18.8%,万古霉素耐药率5.7%。
  • MDR罕见(1.7%),碳青霉烯类和氟喹诺酮类耐药率低,检出1株氟喹诺酮耐药RT027。

核心结论

  • 澳大利亚大多数艰难梭菌分离株对CDI治疗推荐药物(万古霉素、甲硝唑、非达霉素)未显示敏感性降低。
  • 碳青霉烯类和氟喹诺酮类耐药率低,MDR不常见,但克林霉素耐药频繁。

研究设计与样本

  • CDARS研究为澳大利亚全国纵向艰难梭菌感染监测。
  • 3年间通过5个州10个诊断微生物实验室网络收集1091株艰难梭菌。
  • 采用CLSI琼脂掺入法检测9种抗菌药物敏感性。

主要发现

  • 所有菌株对甲硝唑、非达霉素、利福昔明和阿莫西林/克拉维酸敏感。
  • 耐药率:美罗培南0.1%(1/1091)、莫西沙星3.5%(38/1091)、万古霉素5.7%(62/1091)。
  • 克林霉素耐药常见(85.2%;929/1091),其次为头孢曲松(18.8%;205/1091)。
  • 非达霉素体外活性[几何平均MIC(GM)=0.101 mg/L]优于万古霉素(1.700 mg/L)和甲硝唑(0.229 mg/L)。
  • MDR艰难梭菌(对≥3类抗菌药物耐药)患病率低(1.7%;19/1091),检出1株氟喹诺酮耐药RT027。

临床怎么用

  • CDI治疗可依据当地耐药监测数据选择万古霉素、甲硝唑或非达霉素。
  • 克林霉素耐药率高,经验性使用克林霉素需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clostridioides difficile was listed as an urgent antimicrobial resistance (AMR) threat in a report by the CDC in 2019. AMR drives the evolution of C. difficile and facilitates its emergence and spread. The C. difficile Antimicrobial Resistance Surveillance (CDARS) study is nationwide longitudinal surveillance of C. difficile infection (CDI) in Australia. OBJECTIVES: To determine the antimicrobial susceptibility of C. difficile isolated in Australia between 2015 and 2018. METHODS: A total of 1091 strains of C. difficile were collected over a 3 year period by a network of 10 diagnostic microbiology laboratories in five Australian states. These strains were tested for their susceptibility to nine antimicrobials using the CLSI agar incorporation method. RESULTS: All strains were susceptible to metronidazole, fidaxomicin, rifaximin and amoxicillin/clavulanate and low numbers of resistant strains were observed for meropenem (0.1%; 1/1091), moxifloxacin (3.5%; 38/1091) and vancomycin (5.7%; 62/1091). Resistance to clindamycin was common (85.2%; 929/1091), followed by resistance to ceftriaxone (18.8%; 205/1091). The in vitro activity of fidaxomicin [geometric mean MIC (GM) = 0.101 mg/L] was superior to that of vancomycin (1.700 mg/L) and metronidazole (0.229 mg/L). The prevalence of MDR C. difficile, as defined by resistance to ≥3 antimicrobial classes, was low (1.7%; 19/1091). CONCLUSIONS: The majority of C. difficile isolated in Australia did not show reduced susceptibility to antimicrobials recommended for treatment of CDI (vancomycin, metronidazole and fidaxomicin). Resistance to carbapenems and fluoroquinolones was low and MDR was uncommon; however, clindamycin resistance was frequent. One fluoroquinolone-resistant ribotype 027 strain was detected.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Putsathit P, Hong S, George N, et al. Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18. J Antimicrob Chemother. 2021. PMID: 33895826. doi:10.1093/jac/dkab099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。